GH-56

GH-56 is a small molecule inhibitor targeting protein arginine methyltransferase 5 (PRMT5), specifically designed as an MTA-cooperative PRMT5 inhibitor. It demonstrates potent inhibition of symmetric dimethylarginine (SDMA) in MTAP-deleted cancer cells with high selectivity over MTAP wild-type cells. In preclinical studies, GH-56 showed strong anti-tumor activity and good safety profiles in models of MTAP-deleted cancers. The drug is being developed by Qinhao Pharmaceutical (Suzhou) for the treatment of neoplasms, particularly those characterized by methylthioadenosine phosphorylase (MTAP) deletion. Its current highest development phase is Phase 1 clinical trials for advanced solid tumors with MTAP deletion[1][3][6].